Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy

Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy

Sponsors

Lead Sponsor: Universitair Ziekenhuis Brussel

Source Universitair Ziekenhuis Brussel
Brief Summary

Somatostatine induces a dose-dependent reduction of postprandial plasma cholecystokinin (CCK) secretion with a concomitant inhibition of postprandial gallbladder contraction, abolishing almost completely bile salts output from the gallbladder. Somatostatine is also known to decrease acid production with significant increase of intragastric pH. In this way, somatostatine could influence acid as well as non-acid reflux by decreasing gallbladder emptying and decreasing acid secretion.

Purpose of the study is to evaluate the efficacy of lanreotide autogel 120 mg on symptoms and endoscopic lesions in patients with an endoscopic gastrointestinal reflux esophagitis that cannot be controlled with classic therapy.

Detailed Description

Patients presenting with persistent esophagitis on endoscopy while on proton pump inhibitors (PPI) treatment will receive a maximal therapy consisting of 2 x 40 mg of PPI before the meals (morning and evening) and a H2 blocker before bedtime (standard practice). They will be reevaluated endoscopically and clinically 2 months later (standard practice). If reflux persists, objectivized by impedancemetry (standard practice), they will be asked to participate in this study.

Lanreotide autogel 120 mg deep subcutaneously every 4 weeks will be added to the treatment. A total of 3 injections per patient have been foreseen in this proof of concept study.

Patients will be reevaluated clinically after 2, 4 and 8 weeks. At the end of the study a new upper gastrointestinal endoscopy and impedancemetry will be performed.

Overall Status Unknown status
Start Date April 2014
Completion Date April 2016
Primary Completion Date December 2015
Phase Phase 2
Study Type Interventional
Primary Outcome
Measure Time Frame
Los Angeles criteria for reflux esophagitis 4 weeks after the last injection with lanreotide
Enrollment 10
Condition
Intervention

Intervention Type: Drug

Intervention Name: Lanreotide

Arm Group Label: Lanreotide

Other Name: Somatuline

Eligibility

Criteria:

Inclusion Criteria:

- Persistent endoscopic reflux in spite of maximal medical therapy with PPI 2 x 40 mg (before breakfast and dinner) and 300 mg of H2 blocker ranitidine (at bedtime).

The Los Angeles classification (LA) will be used to evaluate endoscopic reflux. Any distal esophageal ulcer with negative biopsy is also diagnostic for reflux.

Persistent reflux is defined as:

No reflux complaints but continuing endoscopic lesions and positive impedancemetry.

Reflux complaints with continuing endoscopic lesions and positive impedancemetry.

Reflux complaints without endoscopic lesions but positive impedancemetry.

Exclusion Criteria:

- Pregnancy or inadequate anticonception, breast feeding.

- Negative impedancemetry.

- Diabetes.

- Placement of a gastric ring for weight loss.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
Kim Moubax, Assistent Study Chair University hospital of Brussels, Laarbeeklaan, Jette
Overall Contact

Last Name: Kim Moubax, Assistent

Phone: 003224749346

Phone Ext.: 0032476486103

Email: [email protected]/[email protected]

Location
Facility: Contact: Contact Backup: Investigator: University Hospital of Brussels Kim Moubax, Assistent 003224749346 0032476486103 [email protected]/[email protected] kim moubax, assistent Principal Investigator
Location Countries

Belgium

Verification Date

January 2014

Responsible Party

Type: Principal Investigator

Investigator Affiliation: Universitair Ziekenhuis Brussel

Investigator Full Name: Kim Moubax

Investigator Title: Dr. Kim Moubax, gastro-enterology

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: Lanreotide

Type: Experimental

Description: Lanreotide autogel 120mg injection every 4 weeks (every patient will receive 3 injections)

Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

Source: ClinicalTrials.gov